30 results about "Insulin regulation" patented technology

Disclosed are botanically based compositions and methods useful for the treatment of metabolic syndrome and diabetes type 2. Compositions, kits, and methods are additionally disclosed for means to augment the activity of identified glucose and insulin regulating drugs.

Novel non-coding sequences isolated upstream of the human IRS-2 gene are disclosed as markers for the prediction and / or diagnosis of IRS-2 related metabolic disorders or diseases, such as diabetes. The sequences also fiction as markers in a method and assay for evaluating the insulin regulating, i.e. insulin sensitizing or inhibiting properties of drug candidate substances, e.g. a method and assay for high throughput screening. The sequences and / or information derived therefrom can also be used for influencing the expression of the IRS-2 gene, e.g. in the therapy of IRS-2 related metabolic disorders, such as diabetes.

The invention concerns RAC-PK and fragments thereof, as well as activators and inhibitors of RAC-PK for use as medicaments, particularly in the treatment of diseases concerned with abnormalities in processes modulated by insulin, such as cellular proliferation, insulin deficiency and / or excess blood sugar levels. Moreover, the invention provides RAC-PK for use in screening potential mimics or modulators thereof. A method for screening for agents capable of affecting the activity of GSK3 is also disclosed. The invention further provides a screening kit comprising the RAC-PK as an active principle, and a method for screening compounds which are candidate mimics or modulators of RAC-PK activity comprising detecting specific interactions between the candidate compounds and RAC-PK. There is also provided a process for activating RAC-PK comprising treatment thereof with a phosphatase inhibitor.

The invention discloses a prescription of a traditional Chinese medicine capable of activating insulin for regulating hyperglycemia, as well preparation and application methods of the traditional Chinese medicine. The traditional Chinese medicine is prepared from the following raw materials: astragalus membranaceus, rhizoma polygonati, poria cocos, roasted rhizoma atractylodis macrocephalae, the root of kudzu vine, American ginseng, schisandra chinensis, cortex lycii radicis, dried rehamnnia root, prepared rehamnnia root, willow sprouts, sticktight, purslane, liquorice, angelica sinensis, ginseng, agilawood, persimmon leaves, rhizoma anemarrhenae, vinegar turtle, salted cortex phellodendr, grifola, endothelium corneum gigeriae galli, lysimachia christinae hance, loofah sponge, propolis, balsam pear, medicated leaven, malt, safflower carthamus, potentilla discolor, hawthorn fruits, fleece-flower root, fructus rosae laevigatae, the root of red-rooted salvia, sculellaria barbata, stevia rebaudian, corn stigma, winter folium mori, platycodon grandiflorum, radix polygonati officinalis, Chinese yam, herba epimedii and fruits of Chinese wolfberries. The traditional Chinese medicine capable of activating insulin for regulating hyperglycemia provided by invention can promote blood glucose to by synthesized into glycogen, accelerate oxygenolysis of blood glucose, promote blood glucose to be converted into nonsugar substances including fat, and also can inhibit the decomposition of liver glycogen, and conversion from the nonsugar substances to glucose, so that the content of blood glucose is reduced, and the curative effect is significant.

Novel non-coding sequences isolated upstream of the human IRS-2 gene are disclosed as markers for the prediction and / or diagnosis of IRS-2 related metabolic disorders or diseases, such as diabetes. The sequences also fuction as markers in a method and assay for evaluating the insulin regulating, i.e. insulin sensitizing or inhibiting properties of drug candidate substances, e.g. a method and assay for high throughput screening. The sequences and / or information derived therefrom can also be used for influencing the expression of the IRS-2 gene, e.g. in the therapy of IRS-2 related metabolic disorders, such as diabetes.

The present invention proposes a blood-sugar-lowering effective part of Dendrobium bougainvillea. The effective part is dried and pulverized stems of Dendrobium bougainvillea, then refluxed with ethanol solution to extract, and suction-filtered the extract to obtain the total extract; the total extract is dissolved in water, successively Different solvents are used for extraction to obtain extracts of four extraction parts; finally, the extracts of each extraction part are concentrated and evaporated to dryness to obtain four polar parts. The effective hypoglycemic part: Part B was separated and purified to obtain compounds with unique structures, isoneeutinin and 26-O-neutigenin glucoside, which were found to be active ingredients by hypoglycemic tests. The present invention also proposes the application of the above effective parts and active ingredients. The extracts from various parts of the Dendrobium bougainvillea of ​​the invention can promote the consumption of glucose by insulin-resistant HepG2 cells. Isonecinogenin and 26‑O‑Neutygenin glucoside restore insulin regulation of blood sugar by improving insulin resistance.

The invention relates to the foodstuff processing field, and particularly relates to a spirulina cake and the manufacturing method. The invention provides a spirulina cake, which takes spirulina as the raw material for making the cake; the components of the raw materials for making the spirulina cake and the proportion and the making technology are researched; by multitime tests and mouthfeel analysis, the cake is tasty while keeping the nutrition value and flavor of the spirulina. According to the formula, xylitol is taken as a sweetener. Because the xylitol makes people feel cool and refreshing, and the xylitol metabolism won't be adjusted by insulin, the obtained spirulina cake can be used to serve the diabetic patients. According to the spirulina cake manufacturing method, the mixing sequence of each raw material and the processing condition is tested by multiple times and the mouthfeel is analyzed to obtain an optimum manufacturing method. The mouthfeel of the cake is further improved; the cake is tasty while keeping the nutrition value and the flavor of the spirulina.

The present invention provides a combination comprising at least two of the following: (i) an insulin modulator, (ii) an immunosuppressive agent and (iii) an aldosterone antagonist, for instance a combination comprising at least two of (i) exenatide, or a functional derivative or analog thereof, or a pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analog thereof, or a pharmaceutically acceptable salt thereof; and (iii) potassium canrenoate, or a functional derivative or analog thereof. Said combinations are suitable for cardioprotection and for treating and / or preventing ischemia and / or reperfusion injury. Further aspects of the invention relate to pharmaceutical products and pharmaceutical compositions comprising said combinations according to the invention, and methods of treatment using the same.

The present invention relates to a method for the treatment of fibrosis, in particular cardiac fibrosis, comprising the administration of an inhibitor of insulin-regulated aminopeptidase (IRAP). Preferable the IRAP inhibitor is chosen from the group including HFI-419, HA-08, AL-40, HFI-437, Val-Tyr-Ile-His-Pro-Phe (otherwise known as angiotensin IV or ANG IV), c[Cys-Tyr-Cys]-His-Pro-Phe, and c[Hcy-Tyr-Hcy]-His-Pro-Phe.

The present invention provides a combination of compounds capable of modulating xenin activity and, insulin secretion and weight gain. The invention also provides methods for modulating GIP activity and insulin secretion in a subject, by modulating xenin activity in the subject.

The invention relates to the field of food processing, in particular to a spirulina and Chinese cymbidium cake and a making method thereof. Spirulina and Chinese cymbidium leaves serve as raw materials for making the cake, the composition and ratio of the raw materials used for making the spirulina and Chinese cymbidium cake and the making technology are studied, the nutritional value and flavor of the cake are preserved, and meanwhile the delicious taste of the cake is ensured; in the formula of the cake, xylitol is used as a sweetening agent and produces a cool feeling in the mouth, xylitol metabolism is not regulated by insulin, and therefore the prepared spirulina andChinese cymbidium cake can be eaten by patients with diabetes. According to the making method of the spirulina and Chinese cymbidium cake, the mixing sequence of the raw materials and the processing condition are tested for many times, the taste is evaluated, the optimal making method is thus obtained, and especially, Chinese cymbidium leaf juice serves as a sandwiched layer of the cake instead of being added before baking; the nutritional value and flavor of the spirulina and the Chinese cymbidium are preserved, and meanwhile the delicious taste of the cake is ensured.

The present invention provides a combination comprising at least two of the following: (i) an insulin modulator, (ii) an immunosuppressive agent and (iii) an aldosterone antagonist, for instance a combination comprising at least two of (i) exenatide, or a functional derivative or analogue thereof, or a pharmaceutically acceptable salt thereof; (ii) cyclosporine, or a functional derivative or analogue thereof, or a pharmaceutically acceptable salt thereof; and (iii) potassium canrenoate, or a functional derivative or analogue thereof. Said combinations are suitable for cardioprotection and for treating and / or preventing ischemia and / or reperfusion injury. Further aspects of the invention relate to pharmaceutical products and pharmaceutical compositions comprising said combinations according to the invention, and methods of treatment using the same.

Embodiments of a testing method suitable for diabetic persons to optimize their administered insulin dosage, in particular a basal rate testing method, comprise collecting one or more sampling sets of biomarker data, wherein each sampling set comprises a sufficient plurality of non-adverse sampling instances and wherein each sampling instance comprises an acceptable biomarker reading at a single point in time recorded upon compliance with adherence criteria, determining a biomarker sampling parameter from each sampling set, comparing the biomarker sampling parameter to a target biomarker range, calculating an insulin adjustment parameter associated with the biomarker sampling parameter if the biomarker sampling parameter falls outside the target biomarker range, adjusting the insulin dosage by the insulin adjustment parameter if the biomarker sampling parameter falls outside the target biomarker range and if the insulin dosage does not exceed maximum dosage, and exiting the testing method if the adjusted insulin dosage is optimized. The insulin dosage is optimized when one or more biomarker sampling parameters fall within a target biomarker range.

The invention provides an insulin control method, device and equipment, and relates to the field of blood glucose control. The method comprises the steps: receiving a blood glucose control target instruction for a human body; detecting physiological parameters in the human body to obtain a human body physiological parameter set St at the moment t; inputting the physiological parameter set St to aninsulin control model, and obtaining insulin dosage Nt needed by the human body at the moment t; and iteratively repeating the above steps at the t+1 moment. The insulin control model in the scheme is obtained by training a deep deterministic strategy gradient model; according to the measured glucose distribution, the daily basic insulin rate and the ratio of insulin to carbohydrate of each humanbody are optimized, human body characteristics in a daily blood glucose curve can be learned in real time, and a personalized insulin regulation scheme is provided; and the method can adapt to humanbody blood glucose values which are rapidly and dynamically changed, so that the blood glucose is maintained within a reasonable range.

The present invention provides a combination of compounds capable of modulating xenin activity and, insulin secretion and weight gain. The invention also provides methods for modulating GIP activity and insulin secretion in a subject, by modulating xenin activity in the subject.

The invention concerns RAC-PK and fragments thereof, as well as activators and inhibitors of RAC-PK for use as medicaments, particularly in the treatment of diseases concerned with abnormalities in processes modulated by insulin, such as cellular proliferation, insulin deficiency and / or excess blood sugar levels. Moreover, the invention provides RAC-PK for use in screening potential mimics or modulators thereof. A method for screening for agents capable of affecting the activity of GSK3 is also disclosed. The invention further provides a screening kit comprising the RAC-PK as an active principle, and a method for screening compounds which are candidate mimics or modulators of RAC-PK activity comprising detecting specific interactions between the candidate compounds and RAC-PK. There is also provided a process for activating RAC-PK comprising treatment thereof with a phosphatase inhibitor.

The invention relates to an insulin regulating blood sugar control caliper, which comprises a long-strip-shaped base ruler (1) and a long-strip-shaped slide ruler (2), wherein the sliding ruler is embedded in a chute (6) formed in the base ruler; scales (3) for indicating the blood sugar values of the former times are marked on the upper edge (7) of the chute (6) of the base ruler along the length direction; the values of the scales are gradually increased from the left side to the right side; scales (4) used for indicating the insulin regulating quantity are marked on the lower edge (8) of the chute (6) of the base ruler along the length direction; scales (5) for indicating the blood sugar value of the current time are marked on the upper edge of the slide ruler along the length direction; the values, the gradually changing direction and the interval sizes of the scales (5) are identical to those of the scales for indicating the blood sugar values of the former times marked on the upper edge of the chute of the base ruler; scales (9) for indicating the blood sugar value of the current time are also marked on the lower edge of the slide rule along the length direction. The insulin regulating blood sugar control caliper has the advantages that the slide ruler can move according to the blood sugar change condition of a patient; the correct regulating quantity of the insulin injection can be found out; the clinic use is convenient; the complicated calculation is avoided.

The present disclosure provides a polyherbal composition for preventing and alleviating Polycystic ovary syndrome. The composition comprises an insulin regulator selected from Cinnamomum zeylyanicum and Trigonella foenum, a blood sugar regulator selected from Garcinea cambogia and Emblica officinalis, a cholesterol lowering agent selected from Linum usittatissimum and Tribulus terrestris, a prolactin regulator selected from Vitex agnus-castus and Trachyspermum ammi, a cyst shrinking component selected from Zingiber officinale and Putranjiva roxburghii, an androgen regulator selected from Ocimum sanctum, Glycyrrhiza glabra and Mentha spicate, an adrenal gland regulator selected from Withania somnifera and Sesamum indicum, an inositol containing component selected from Oryza sativa and Cicer arietinum, a binder selected from Ferula foetida and Prunus amygdalus along with a pharmaceutically acceptable excipient.

The present disclosure provides a polyherbal composition for preventing and alleviating Polycystic ovary syndrome. The composition comprises an insulin regulator selected from Cinnamomum zeylyanicum and Trigonella foenum, a blood sugar regulator selected from Garcinea cambogia and Emblica officinalis, a cholesterol lowering agent selected from Linum usittatissimum and Tribulus terrestris, a prolactin regulator selected from Vitex agnus-castus and Trachyspermum ammi, a cyst shrinking component selected from Zingiber officinale and Putranjiva roxburghii, an androgen regulator selected from Ocimum sanctum, Glycyrrhiza glabra and Mentha spicate, an adrenal gland regulator selected from Withania somnifera and Sesamum indicum, an inositol containing component selected from Oryza sativa and Cicer arietinum, a binder selected from Ferula foetida and Prunus amygdalus along with a pharmaceutically acceptable excipient.

The invention concerns RAC-PK and fragments thereof, as well as activators and inhibitors of RAC-PK for use as medicaments, particularly in the treatment of diseases concerned with abnormalities in processes modulated by insulin, such as cellular proliferation, insulin deficiency and / or excess blood sugar levels. Moreover, the invention provides RAC-PK for use in screening potential mimics or modulators thereof. A method for screening for agents capable of affecting the activity of GSK3 is also disclosed. The invention further provides a screening kit comprising the RAC-PK as an active principle, and a method for screening compounds which are candidate mimics or modulators of RAC-PK activity comprising detecting specific interactions between the candidate compounds and RAC-PK. There is also provided a process for activating RAC-PK comprising treatment thereof with a phosphatase inhibitor.

The invention discloses a preparation method of raspberry alpha-dry red wine. The preparation method comprises the following steps: (1) measuring fresh or thawed red raspberry fruits, and blanching ina water bath; (2) squeezing the red raspberry fruits after being blanched in step (1) by using a juicing machine, and separating to obtain red raspberry juice; (3) adjusting the acidity of the red raspberry juice by using edible alkaline buffering salt, fruits, vegetables or edible fungus; (4) when the pH of the red raspberry juice reaches 3.1 to 3.6, performing the fermentation; (5) after the fermentation is ended, guiding the upper layer fermented wine liquid into an ageing tank, adjusting the sweetness by using a non-nutritional sweetening agent, and ageing for 90 to 120 days at 20 to 25 DEG C; and (6) performing the membrane filtering and packaging for the aged wine. According to the raspberry alpha-dry red wine, by adding the non-nutritional sugar, the problem of the acerb taste of the raspberry dry red wine can be solved, and the dry red wine product can adapt to the dietary habit of Chinese people; the non-nutritional sugar does not need the insulin to adjust the metabolism, and no great energy is produced, so that the raspberry alpha-dry red wine is suitable for various people to eat such as the fat consumers, consumers with high blood sugar and the like.

The present invention relates to compounds of formula (I) compositions, in particular pharmaceutical compositions, and medicaments comprising at least one compound of formula (I). The invention also relates to the use of such a compound for manufacturing a medicament. In particular the medicament and the pharmaceutical composition are intended to treat diseases linked with insulin regulation problems, such as diabetes. This invention aims also to methods for treating or preventing such diseases.

The invention belongs to the technical field of nutritional food processing, and particularly relates to a drinking water solution for supplementing organic selenium for human bodies. The drinking water solutioncomprises the following specific components: water, 80-120 [mu]g / L of selenocysteine and 0.05-0.15 g / L of nisin. The drinking water solution for supplementing the organic selenium to the human body comprises the following specific preparation steps: 1, extracting selenocysteine from animal food by using a biological method for sufficient standby application, so that selenium can be effectively supplemented to the human body, replication of viruses can be inhibited, cell repair can be participated, various viral diseases can be prevented, anti-oxidation effect can be achieved so as to remove damage of free radicals to human bodies and achieve the effect of delaying senescence, blood sugar can be regulated without depending on insulin, diabetic complications can be delayed, relieved and prevented, cancer cells can be killed, toxic and side effects of radiotherapy and chemotherapy can be relieved, toxicity of anti-cancer drugs to kidneys, bone marrow and intestines and stomach can be reduced, and pain of patients can be relieved.

Specifically, the invention relates to the discovery and development of an effective cryogenic gastrointestinal triggering device that artificially activates the gastrointestinal tract's involuntary intestinal functions in the application process. Generally, several of the invention's functions relates to a method for decreasing undesirable bacteria in the intestinal tract for achieving a healthy glucose and insulin regulation, inclusive intestinal and body health, and metabolic fitness. The invention has both human and animal application.

The present invention relates to compounds of formula (I) compositions, in particular pharmaceutical compositions, and medicaments comprising at least one compound of formula (I). The invention also relates to the use of such a compound for manufacturing a medicament. In particular the medicament and the pharmaceutical composition are intended to treat diseases linked with insulin regulation problems, such as diabetes. This invention aims also to methods for treating or preventing such diseases.